Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Blue Sky scratches head lice from portfolio

Blue Sky Venture Capital has exited a head lice treatment company after it entered into a $278 million commercial agreement with Indian-based Dr. Reddy's Laboratories.

Upgrade your subscription to access this article

And gain access to:
  • All archived news content
  • Access to the Financial Standard app
  • Home page news customisation
  • Financial Standard 's fortnightly newspaper
  • 25% discount on tickets to networking events
And more
Already A Subscriber?

Read more: Blue Sky Venture CapitalLaboratoriesAustraliaIndian-based Dr. ReddyBlue Sky Private EquityHatchtechAdelaideAndrew ChampionBlue Sky Alternative InvestmentsDr Elaine SteadGM HotelsGreg MatilandIndependent Pub GroupQueensland Biotechnology FundUniseedUniversity of Melbourne